“Perhaps the arterial glycocalyx will become the most important [drug target] for future early prevention of people at risk of cardiovascular disease.”
A.J. Drake-Holland and M.I.M. Noble: Update on the Important New Drug Target in
Cardiovascular Medicine – the Vascular Glycocalyx
ARTEROSIL RESEARCH STUDIES OVERVIEW
A brief summary of studies of Arterosil, a specific glycocalyx regenerating compound (GRC) for the restoration of endothelial function and regression of atherosclerotic plaque.
Three types of studies are reported: cellular, animal and human. Each study focused on a different effect of Arterosil, a nutraceutical that contains a patent-pending endothelial glycocalyx regenerating compound (GRC).
Atherosclerotic Plaque Regression Study Hospital in Beijing — Human Pilot (still underway) Preliminary Findings to Date: 47% and 64% regression of atherosclerotic plaque lipid-rich necrotic core (LRNC) in 60 days
This ongoing study employs MRI PlaqueView®, an FDA-approved technology for advanced plaque characterization and quantification, to analyze the composition and morphology of atherosclerotic plaque including the lipid rich necrotic core (LRNC) of carotid plaque.
Following baseline MRI, two (2) Arterosil capsules per day were administered for 60 days. Post MRI taken at 69 days.
Lipid Rich Necrotic Core (LRNC) Volume – Baseline, Post and Percent Regression
Slice-by-Slice Baseline to Post Comparisons at Varying Distances from Landmark
Distance from Landmark: 2mm
Distance from Landmark: 4mm
Distance from Landmark: 6mm
This pilot study is still underway in Beijing. A larger, multi-center study is currently under design for implementation in the United States in 2019.
Leukocyte Adhesion Study Maastricht University — Animal Study Finding: Arterosil prevents the increase of leukocyte adhesion and inhibits endothelium-mediated inflammation
Experiment conducted by examining cremaster venules of male mice in vivo.
The endothelial glycocalyx was removed using hyaluronidase enzyme
Numbers of patrolling leukocytes and adhering leucocytes were measured using intravital microscope
The data showed a significant increase of leukocyte adhesion, with a simultaneous loss of patrolling leukocytes, after enzymatic removal of the glycocalyx. Arterosil normalized leukocyte adhesion and leukocyte patrolling activity.
Glycocalyx Regeneration Study Chinese Academy of Sciences — Cellular Study Finding: Arterosil repairs and regenerates glucose damaged endothelial glycocalyx
A multi-layer microfluidic chip model was created to mimic the human endothelial glycocalyx under relevant physiological and pathological conditions
The model simulates activities and mechanics of the endothelium with glycocalyx to various biological stimuli
The “lab-on-a-chip” allows for rapid pathological research of the endothelial glycocalyx in vitro
The study established a significant increase of leukocyte adhesion, and loss of patrolling leukocytes, after enzymatic removal of the glycocalyx. Arterosil normalized leukocyte adhesion and leukocyte patrolling activity.
Endothelial Function as Measured by Arterial Elasticity Baylor Heart Institute Campus – Human Study Finding: Arterosil improved endothelial function – arterial elasticity increased by an average of 89.6%
19 healthy human subjects were randomly recruited (11 females age 22 to 64, 8 males age 30 to 60)
Vascular elasticity was measured at baseline and post administration of Arterosil, every 30 minutes for 3 hours, using an FDA Class II plethysmography device
Arterosil increased arterial elasticity by an average of 89.6%, an indication of significant improvement of endothelial function.
IMPORTANT NOTICE: The information on this webpage is for licensed healthcare practitioner education only, and is not to be disseminated to the general public.
Calroy Health Sciences, LLC 11445 E. Via Linda Scottsdale, AZ 85259 1-800-609-6409 1-480-454-5566 (fax)
The section you selected contains information intended for licensed healthcare practitioners only. Please certify that you are a licensed healthcare practitioner by clicking the "yes" link below or click "No" to return to the previous page.